Hot Money Fuels China Biotech ‘Me-Different’ Ambitions
This article was originally published in PharmAsia News
Adagene is the latest antibody firm to receive millions in financing, adding to a growing list of upcoming Chinese biotechs looking to differentiate in a largely unpenetrated yet competitive biologics market.
You may also be interested in...
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.